Comments by DR.Guttler
While the majority of clinical thyroidologists still consider LT4 as then treatment of choice for hypothyroidism, the patients who are unhappy with LT4 therapy were the ones most likely to answer this survey. In 43 years in clinical thyroid practice 99% of patients are happy on the right dose and have symptoms on the wrong dose. Only a few ask for a change to pig thyroid or combinations or just Cytomel T3.
Even Dr.Fawell who reviewed this article in Thyroid said”It is important to realize that this was a voluntary survey and respondents may not represent the majority of the >10 million individuals in the U.S. with hypothyroidism”. Indeed, the majority of hypothyroid patients appear to do well on levothyroxine monotherapy”. The complainers are the ones to answer and write some of these bad things about their treatment with LT4.
10 million hypothyroid patient’s can’t be wrong. Only a few have real reasons for failed LT4 therapy. Those few with genetic problems and a few with allergies to the dye in the pills. The rest are just unhappy that LT4 did not fix all their symptoms, and that the persistent symptoms were not due to thyroid.
10,000,000 hypothyroid patients
9,990,000 happy thyroid patients on LT4
Less than 10,000 unhappy thyroid patients with a few of them with a real reason for failed treatment with a rare genetic
defect on T4/T3 conversion.
In 43 years I have no one on pig thyroid, or T4/T3 combinations.I have one on cytomel only, and several on gelcap LT4.
I have rarely had to switch to the write 0.05
In any clinical practice it is clear that some hypothyroid patients may continue to complain of symptoms they attribute to hypothyroidism, even after being on what is considered adequate therapy. This leads some patients to switch physicians multiple times and to use unconventional/ alternative therapies. Indeed, the ongoing clinical challenge in treating hypothyroidism is the many nonspecific symptoms which may be caused by multiple other non-thyroid-related disorders.
To address these issues, and to review the current state of hypothyroidism evaluation and management, the American Thyroid Association (ATA) held a symposium entitled Hypothyroidism — Where are we now? in the spring of 2017. In the two months before the symposium, patients with hypothyroidism were invited to complete the online ATA Hypothyroidism Treatment Survey that was created by the program committee members. The survey was posted on the ATA website, emailed to patients in the ATA database, distributed to members of the Alliance for Thyroid Patient Education, and further distributed on the websites and social media of multiple patient advocacy groups that are members of the ATA Alliance for Thyroid Patient Education. The preliminary results of the survey were presented and discussed with a panel of patients with hypothyroidism at the symposium. The final analysis of the survey results will be published in the June issue of Thyroid and Drs. Angela Leung and Eric Stevens summarized the paper for a future issue of Clinical Thyroidology. In this issue, Dr. Sarah Peterson, the lead author of this important paper, has provided a summary of the paper for CTFP in advance of its’ publication. In the interest of full disclosure, I am also an author of this paper, and the full list of authors is included in the summary.
The ATA Hypothyroidism Survey confirmed that dissatisfaction with treatments and doctors does affect a significant group of hypothyroid patients. In addition, the vast majority of respondents rated that living with hypothyroidism has a major effect on their life and that the development of additional hypothyroidism treatment options is vitally needed. In terms of the current therapeutic options, animal-derived desiccated thyroid extract (DTE)
appears to be preferred by the survey respondents over T4/T3 combination therapy and T4 monotherapy. However, even the DTE group reported continued symptoms attributed to hypothyroidism. I am sure that this paper will be illuminating, and controversial, as hypothyroidism is considered by many physicians to be a medical disorder that is rather straightforward to treat.
It is important to realize that this was a voluntary survey and respondents may not represent the majority of the >10 million individuals in the U.S. with hypothyroidism. Indeed, the majority of hypothyroid patients appear to do well on levothyroxine monotherapy. While physicians will often ascribe symptoms persisting despite “adequate” thyroid replacement therapy to non-thyroid causes, some recent studies suggest that there may be some genetic influences on the ability to respond to levothyroxine therapy. In any event, the ATA Hypothyroidism Survey does make clear that more research is needed in this area and that future studies on the optimal management of hypothyroidism are necessary.
— Alan P. Farwell, MD, FACE